Quick Answer
RenovoRx, Inc. reported Operating Income of -$12.51 million for fiscal year 2025.
RenovoRx, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$12.51M | -14.0% |
| 2024 | -$10.97M | +3.7% |
| 2023 | -$11.40M | -14.5% |
| 2022 | -$9.95M | -75.5% |
| 2021 | -$5.67M | -77.0% |
| 2020 | -$3.20M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.20M | -13.2% | -19.5% |
| June 30, 2025 | -$2.68M | +11.7% | +13.9% |
| March 31, 2025 | -$3.11M | -25.6% | -10.0% |
| September 30, 2024 | -$2.83M | +5.2% | +6.8% |
| June 30, 2024 | -$3.03M | +10.1% | -22.5% |
| March 31, 2024 | -$2.48M | +24.1% | +17.0% |
| September 30, 2023 | -$2.98M | -38.0% | +11.6% |
| June 30, 2023 | -$3.38M | -29.1% | -3.5% |
- RenovoRx, Inc. showed a decrease of -14.0% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, RenovoRx, Inc.’s operating income has declined by 290.4% (from -$3.20 million to -$12.51 million).
- The most recent figure is from RenovoRx, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: